News

MBF Bioscience Announces the Acquisition of Vidrio Technologies

MBF Bioscience, a leading provider of bioscience image analysis tools, announced that it has completed the acquisition of Vidrio Technologies. Terms of the transaction were not disclosed.

Based in Ashburn, VA, Vidrio is a fast-growing provider of software and hardware components for laser scanning and two photon microscopes.

“Vidrio Technologies builds widely loved tools for researchers who utilize two photon and laser scanning microscopes to answer some of the toughest questions in biology,” says MBF Bioscience Founder and President Jack Glaser. “They have assembled a truly special team of engineers and I am thrilled that MBF will have the opportunity to be a part of the continued development, release, and support of Vidrio’s impressive products.”

“The team at Vidrio couldn’t be more excited to be joining forces with MBF,” says Vidrio Technologies CEO Bruce Kimmel. “We have grown rapidly in recent years and MBF’s large development team will be a great resource for us as we continue to invest in the development of industry-leading tools for bioscience researchers.”

Georg Jaindl, Senior Software Engineer at Vidrio Technologies said, “Vidrio has a pipeline full of exciting new products that we can’t wait to show our customers. By joining forces with MBF, we will be able to build these tools for our customers faster and provide even more responsive technical support than our customers already receive.”

Recent News

04/02/2025

VCU startup wins $800k grant to propel its infection-fighting surgical gel

With an innovation that could advance brain and spinal surgeries, a Virginia Commonwealth University startup has received an $800,000 state grant to support development of its infection-fighting gel. Pascal Medical Corp. is one of four grant recipients to receive awards from Virginia Catalyst, a nonprofit created by the General Assembly and funded by the state’s general

04/02/2025

Quoin Pharmaceuticals Announces Additional Positive ‘Whole Body’ Clinical Data from Ongoing Pediatric Netherton Syndrome Study and Approval to Initiate Testing of a Second Pediatric Patient

Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (the “Company” or “Quoin”), a late clinical stage, specialty pharmaceutical company focused on the development and commercialization of therapeutic products that treat rare and orphan diseases, today announces additional highly positive clinical data from its ongoing Investigator Pediatric Netherton Syndrome (NS) study. After 6 weeks of continued whole body application

04/02/2025

Charlottesville Angel Network Celebrates 10 Years, Surpasses $20 Million in Investments

The Charlottesville Angel Network (CAN), a group of accredited investors dedicated to supporting early-stage ventures, proudly marks its 10th anniversary this month. Since its inception, CAN angel investor members have invested more than $20 million in nearly 80 startups, fostering innovation both locally and beyond. Reflecting on a decade of achievements, CAN has realized returns